How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

365 results for

Intraocular Carbonic Anhydrase Inhibitor

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue

Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) % ophthalmic suspension Drug: Vehicle Drug: Prostaglandin analogue Phase 4 Detailed Description: This study was divided into 2 sequential phases. The Screening/Eligibility Phase included one Screening Visit and two Eligibility Visits, during which subjects washed out of all other intraocular pressure (IOP)-lowering medications and dosed with TRAVATAN Z®, XALATAN®, or LUMIGAN®, 1 drop instilled in each eye once daily for 28 days. Subjects who met all inclusion/exclusion criteria were randomized

2013 Clinical Trials

182. Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®

of Pharmacological Action Physiological Effects of Drugs Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Drug: Travoprost 0.004% ophthalmic solution Phase 4 Detailed Description: This study was divided into 2 sequential phases. The Screening/Eligibility Phase included one Screening Visit and two Eligibility Visits, during which subjects washed out of all other intraocular pressure (IOP)-lowering medications and dosed with TRAVATAN Z®, 1 drop instilled in each eye once daily for 28 days. Subjects who met all inclusion/exclusion criteria were randomized at the second Eligibility Visit. The Treatment

2013 Clinical Trials

183. Orbscan topography in primary open-angle glaucoma. (PubMed)

included any corneal or ocular inflammatory disease, previous ocular surgery, or treatment with carbonic anhydrase inhibitors. The same masked observer performed Goldmann applanation tonometry, ultrasound pachymetry, and Orbscan II topography in all cases. Central corneal thickness, intraocular pressure, and anterior and posterior topographic elevation maps were analyzed and compared between both groups.Patients with POAG had greater forward shifting of the posterior corneal surface than

Full Text available with Trip Pro

2013 Optometry and vision science : official publication of the American Academy of Optometry Controlled trial quality: uncertain

184. Medical versus surgical interventions for open angle glaucoma. (PubMed)

two small trials in more severe OAG, that initial medication (pilocarpine, now rarely used as first line medication) is associated with more glaucoma progression than surgery. Beyond five years, there is no evidence of a difference in the need for cataract surgery according to initial treatment.The clinical and cost-effectiveness of contemporary medication (prostaglandin analogues, alpha2-agonists and topical carbonic anhydrase inhibitors) compared with primary surgery is not known.Further RCTs (...) was associated with marginally less visual field loss at five years than initial medication, (mean difference 0.74 dB (95% CI -0.00 to 1.48). Initial trabeculectomy was associated with lower average intraocular pressure (IOP) (mean difference 2.20 mmHg (95% CI 1.63 to 2.77) but more eye symptoms than medication (P = 0.0053). Beyond five years, visual acuity did not differ according to initial treatment (OR 1.48, 95% CI 0.58 to 3.81).From three trials in more severe OAG, there is some evidence that medication

2012 Cochrane database of systematic reviews (Online)

185. Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH

ETDRS letters (equivalent to approximately 20/80 Snellen). Another ocular pathology (including severe dry eye) that may, in the opinion of the investigator, preventing the administration of an alpha-adrenergic agonist and/or an inhibitor of topical carbonic anhydrase (CAI). Intraocular surgery within the last 6 months. Laser eye surgery in the last 3 months. Any abnormality that prevents a reliable applanation tonometry. Any other condition including severe illness that would make the patient (...) brinzolamide Additional relevant MeSH terms: Layout table for MeSH terms Hypertension Glaucoma Glaucoma, Open-Angle Ocular Hypertension Vascular Diseases Cardiovascular Diseases Eye Diseases Ophthalmic Solutions Latanoprost Brinzolamide Pharmaceutical Solutions Antihypertensive Agents Carbonic Anhydrase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

2012 Clinical Trials

186. The Laser in Pseudoexfoliation (LIP) Study

IOP, a second line agent will be added (β-Blocker unless contraindicated). If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor). Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP. Surgical therapy will be considered if target IOP is not met, or there is high IOP (>35 mmHg) or advanced damage at presentation. Other Names: B-Blocker (...) Carbonic anydrase inhibitor Outcome Measures Go to Primary Outcome Measures : Number of drops (and surgical interventions) needed to reach target IOP. [ Time Frame: Change in IOP at 6 months, 12 months and 2 years (from baseline). ] Percentage success [ Time Frame: At 6 months, 12 months and 2 years ] Proportion of patients in whom SLT (or mono medical therapy) alone achieved target IOP. Secondary Outcome Measures : Correlation of angle pigment grade with IOP reduction from SLT [ Time Frame: 6 months

2012 Clinical Trials

187. Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves

gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID). Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID). Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts (...) in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD) Other Names: Timoptic Trusopt Azopt Alphagan-P Xalatan Travatan Z Lumigan Diamox No Intervention: Control Group Patients randomized to the control group will receive standard of care treatment. They will not be aqueous suppressed within the first three postoperative months unless the bleb hyperencapsulates

2012 Clinical Trials

188. Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil

Agonists Adrenergic alpha-Agonists Adrenergic Agonists Carbonic Anhydrase Inhibitors (...) in Intraocular Pressure (IOP) at 8 Weeks From Baseline (Prior Therapy). [ Time Frame: 8 weeks ] Intraocular pressure was measured by Goldmann applanation tonometry. Data for the worse eye were used for the efficacy analysis. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your

2012 Clinical Trials

189. Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema

and cataract constitute important causes of visual impairment in patients with diabetes. Cataract surgery in patients with diabetic retinopathy is associated with progression of retinopathy. Several modalities such as non-steroidal anti-inflammatory agents, carbonic anhydrase inhibitors, corticosteroids, hyperbaric oxygen, laser photocoagulation and vitrectomy with internal limiting membrane peeling have been tried for managing inflammatory cystoid macular edema. Intravitreal Triamcinolone Acetonide (TA (...) ; Genentech, South San Francisco, California), Bevacizumab (Avastin, Genentech) have been tried in an attempt to improve the visual results. Several modalities such as non-steroidal anti-inflammatory agents, carbonic anhydrase inhibitors, corticosteroids, hyperbaric oxygen, laser photocoagulation and vitrectomy with internal limiting membrane peeling have been tried for managing inflammatory cystoid macular edema13. Intravitreal Triamcinolone Acetonide (TA), a water insoluble steroid, has been shown

2012 Clinical Trials

190. Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America

Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Enzyme Inhibitors Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Carbonic Anhydrase Inhibitors (...) of Medicine related topics: related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: AZARGA® Brinzolamide/timolol maleate fixed combination, 1 drop self-administered in study eye(s) twice a day for 8 weeks Drug: Brinzolamide/timolol maleate fixed combination Other Name: AZARGA® Outcome Measures Go to Primary Outcome Measures : Mean Change in Intraocular Pressure (IOP) From Baseline (Prior Therapy) at Week 8 [ Time Frame: Baseline, Week 8 ] IOP (fluid

2012 Clinical Trials

191. Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Pharmaceuticals International, Inc. More Information Go to Layout table for additonal information Responsible Party: Valeant Pharmaceuticals International, Inc. ClinicalTrials.gov Identifier: Other Study ID Numbers: CD-11-265 First Posted: November 7, 2012 Last Update Posted: April 4, 2019 Last Verified: March 2019 Additional relevant MeSH terms: Layout table for MeSH terms Ocular Hypertension Eye Diseases Brinzolamide Carbonic Anhydrase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological (...) : available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Azopt 1% ophthalmic suspension Ophthalmic suspension Drug: Azopt 1% Azopt 1%, RLD Experimental: Brinzolamide 1% ophthalmic suspension ophthalmic suspension Drug: brinzolamide 1% ophthalmic suspension brinzolamide 1% ophthalmic suspension Outcome Measures Go to Primary Outcome Measures : Intraocular pressure (IOP) at baseline (Eligibility Visit 2) weeks and after treatment. [ Time Frame: 12 weeks ] Secondary Outcome

2012 Clinical Trials

192. Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action (PubMed)

, β-antagonists, prostaglandin analogs and carbonic anhydrase inhibitors. Some of these topical medications exhibit secondary neuroprotective effects independent of their effect on IOP. This review covers the possible mechanisms of neuroprotection stimulated by drugs currently marketed for the lowering of IOP, based on known literature. While the neuroprotective properties of many glaucoma pharmaceuticals are promising from an experimental standpoint, key challenges for the development of new (...) Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action Primary open-angle glaucoma, a long-term degenerative ocular neuropathy, remains a significant cause of vision impairment worldwide. While many risk factors have been correlated with increased risk for primary open-angle glaucoma, intraocular pressure (IOP) remains the only modifiable risk factor and primary therapeutic target. Pharmacologic therapies are administered topically; these include α(2)-agonists

Full Text available with Trip Pro

2012 Expert review of ophthalmology

193. Acetazolamide

From Related Chapters II. Mechanism Carbonic Anhydrase Inhibitor III. Indications treatment and prevention IV. Contraindications V. Dosing Prevention: 125 mg PO bid Start 24 hours before ascent Continue for 72 hours or until acclimitization to highest sleeping altitude at altitude: 125 mg PO qhs Treatment: 250 mg orally twice daily (up to 400 mg twice daily has been sed) Dose range: 125-250 mg PO qd-tid VI. Adverse Effects Peripheral s (common) Images: Related links to external sites (from Bing (...) . This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See for financial assistance information. Ontology: Acetazolamide (C0000981) Definition (NCI) A sulfonamide derivative with diuretic, antiglaucoma, and anticonvulsant properties. Acetazolamide is a non-competitive inhibitor of carbonic anhydrase, an enzyme found in cells in the proximal

2015 FP Notebook

194. Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial. (PubMed)

study. We randomly allocated 39 patients who had been treated with three antiglaucoma eye drops (prostaglandin F(2α) analogues plus beta-blockers and carbonic anhydrase inhibitors) into two groups. Group A (n = 20) were treated with latanoprost-timolol and brinzolamide 1% therapy and Group B (n = 16) were treated with dorzolamide 1%/timolol and latanoprost. Thirty-six patients completed all 12 weeks of this study. The major clinical parameters measured were intraocular pressure (IOP), conjunctive

Full Text available with Trip Pro

2012 Clinical ophthalmology (Auckland, N.Z.) Controlled trial quality: uncertain

195. Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes

surgery within 6 months the eyes with difficulty for the measurement of IOP with the applanation tonometer the subjects with the allergy for PG-analogues or benzalkonium chloride the subjects using the eyedrops excluding those in this study the subjects treated with oral carbonic anhydrase inhibitor the subject with Sjogren syndrome the subjects who can not drop periodically the subjects with the advanced glaucoma or the terminal stage of glaucoma the subjects with the severe ocular complications (...) affect the PG-analogue induced hyperemia or IOP reduction. Condition or disease Intervention/treatment Phase Hyperemia Intraocular Pressure Drug: dicrofenac and travoprost Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 40 participants Allocation: Randomized Intervention Model: Single Group Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: Effect of Non-steroid Anti

2011 Clinical Trials

196. Comparing Eye Pressure Using Maximal Tolerated Local Therapy or Systemic Acetazolamide

for MeSH terms Acetazolamide Anticonvulsants Carbonic Anhydrase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Diuretics Natriuretic Agents Physiological Effects of Drugs (...) trabeculectomy in 3 to 4 weeks. Criteria Inclusion Criteria: Patients with uncontrolled intraocular eye pressure Patients with planed trabeculectomy in 3 to 4 weeks Exclusion Criteria: Patients not meeting the inclusion criteria Patients with known intolerance to acetazolamide Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer

2011 Clinical Trials

197. Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) intraocular pressure (IOP) relative to each of its individual active constituents instilled concomitantly (Brinzolamide+Brimonidine) in patients with open-angle glaucoma or ocular hypertension. Condition or disease Intervention/treatment Phase Open-Angle Glaucoma Ocular Hypertension Drug: Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension Drug: Vehicle Drug: Brinzolamide 1% ophthalmic suspension Drug: Brimonidine tartrate 0.2% ophthalmic solution Phase 3 Detailed Description

2011 Clinical Trials

198. Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%

Eye Diseases Ophthalmic Solutions Brimonidine Tartrate Brinzolamide Pharmaceutical Solutions Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) , 2013 Last Update Posted : May 21, 2013 Sponsor: Alcon Research Information provided by (Responsible Party): Alcon Research Study Details Study Description Go to Brief Summary: The purpose of this study was to evaluate the efficacy and safety of a fixed combination of Brinzolamide/Brimonidine in lowering intraocular pressure (IOP) relative to each of its individual active components in patients with open-angle glaucoma and/or ocular hypertension. Condition or disease Intervention/treatment Phase

2011 Clinical Trials

199. Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

Glaucoma Glaucoma, Open-Angle Ocular Hypertension Vascular Diseases Cardiovascular Diseases Eye Diseases Ophthalmic Solutions Brimonidine Tartrate Brinzolamide Pharmaceutical Solutions Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) . ClinicalTrials.gov Identifier: NCT01297920 Recruitment Status : Completed First Posted : February 17, 2011 Results First Posted : July 4, 2013 Last Update Posted : July 4, 2013 Sponsor: Alcon Research Information provided by (Responsible Party): Alcon Research Study Details Study Description Go to Brief Summary: The purpose of this study was to evaluate the safety and efficacy of a new ophthalmic suspension (Brinz/Brim) in lowering intraocular pressure (IOP) relative to its individual active components

2011 Clinical Trials

200. Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada

Hypertension Glaucoma Glaucoma, Open-Angle Ocular Hypertension Vascular Diseases Cardiovascular Diseases Eye Diseases Timolol Brimonidine Tartrate, Timolol Maleate Drug Combination Maleic acid Brinzolamide Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Enzyme Inhibitors Carbonic Anhydrase Inhibitors Adrenergic alpha-2 Receptor Agonists (...) : July 1, 2014 Last Update Posted : July 1, 2014 Sponsor: Alcon Research Information provided by (Responsible Party): Alcon Research Study Details Study Description Go to Brief Summary: The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior brimonidine 0.2%/timolol 0.5% fixed combination (COMBIGAN®) therapy in patients with open-angle glaucoma or ocular hypertension and uncontrolled intraocular pressure (IOP). Condition or disease Intervention

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>